NAPLEX Quiz: Formulary And Therapeutic Alternatives

What this quiz covers

This quiz focuses on Formulary And Therapeutic Alternatives, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Infliximab-dyyb intravenously at the same mg/kg and interval (correct answer)
2. Adalimumab-atto 40 mg subcutaneously every 2 weeks
3. Infliximab-dyyb 2.5 mg/kg intravenously every 12 weeks
4. Vedolizumab 300 mg intravenously every 8 weeks

Explanation: This question evaluates the appropriate substitution to a formulary-preferred biosimilar for biologic therapy in ulcerative colitis, focusing on equivalence in dosing and administration. The key patient-specific factor is the stable response to infliximab 5 mg/kg every 8 weeks, with a managed mild infusion reaction, requiring a seamless transition without altering efficacy. Infliximab-dyyb at the same mg/kg and interval is optimal as it is a direct biosimilar, ensuring bioequivalence and continuity of care at the infusion center. Adalimumab-atto and vedolizumab are incorrect as they are different biologics with distinct mechanisms and administration routes, potentially disrupting disease control. Reducing the infliximab-dyyb dose or extending the interval is suboptimal, as it deviates from the established effective regimen and risks flare-ups. When switching to biosimilars, always match the originator's dose and schedule to maintain therapeutic outcomes while leveraging cost savings. This strategy promotes formulary compliance and accessibility without compromising patient stability in inflammatory bowel disease management.

Question 2

1. Infliximab-dyyb 3 mg/kg intravenously at weeks 0, 2, and 6, then every 8 weeks
2. Adalimumab-adbm 40 mg subcutaneously every other week (correct answer)
3. Etanercept-szzs 50 mg subcutaneously once weekly
4. Adalimumab-adbm 20 mg subcutaneously every other week

Explanation: This question tests understanding of biosimilar substitution requirements and appropriate dosing equivalence. The patient requires conversion from reference adalimumab to an FDA-approved biosimilar due to insurance requirements. Adalimumab-adbm 40 mg every other week (B) is correct as it maintains the exact same dose and frequency as the reference product, which is required for biosimilar substitution. Infliximab-dyyb (A) is a different TNF inhibitor requiring IV administration, not a biosimilar of adalimumab. Etanercept-szzs (C) is another distinct TNF inhibitor with different dosing. Adalimumab-adbm 20 mg (D) represents half the required dose and would likely result in disease flare. When substituting biosimilars, maintain identical dosing to the reference product and ensure the biosimilar is FDA-approved for the same indication.

Question 3

1. Switch to lisinopril 10 mg by mouth once daily
2. Switch to losartan 50 mg by mouth once daily (correct answer)
3. Switch to aliskiren 150 mg by mouth once daily
4. Switch to losartan 12.5 mg by mouth once daily

Explanation: This question tests knowledge of therapeutic interchange between angiotensin receptor blockers (ARBs) when formulary restrictions exist. The key patient-specific factor is the documented angioedema with lisinopril, which represents an absolute contraindication to all ACE inhibitors due to cross-reactivity risk. Losartan 50 mg daily (B) is the correct answer as it provides equivalent ARB therapy to olmesartan 20 mg with appropriate dosing for this patient with controlled blood pressure. Lisinopril (A) is contraindicated due to the angioedema history, making this a dangerous choice. Aliskiren (C) is a direct renin inhibitor, not an ARB, and is not listed as a formulary option. Losartan 12.5 mg (D) represents an inadequate starting dose that would likely result in loss of blood pressure control. When making formulary substitutions, always verify equivalent dosing between agents and screen for contraindications based on allergy history.

Question 4

1. Switch to semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then 0.5 mg once weekly (correct answer)
2. Switch to sitagliptin 25 mg orally once daily
3. Switch to liraglutide 0.6 mg subcutaneously once weekly
4. Switch to semaglutide 0.25 mg subcutaneously once monthly

Explanation: This question tests formulary substitution among GLP-1 receptor agonists for type 2 diabetes. The key patient-specific factor is the plan preferring weekly semaglutide over dulaglutide, with no pancreatitis history. Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then 0.5 mg once weekly, is optimal for glycemic control and titration safety. Option B uses sitagliptin, different class, while option C is liraglutide at incorrect frequency. Option D suggests monthly dosing, non-standard. A pearl is to titrate GLP-1 agonists slowly to minimize GI effects. Formulary compliance ensures cost-effective diabetes management.

Question 5

1. Switch to fluticasone propionate nasal spray 2 sprays per nostril once daily (correct answer)
2. Switch to fluticasone/salmeterol inhaler 1 inhalation twice daily
3. Switch to loratadine 10 mg orally once daily only
4. Switch to fluticasone propionate nasal spray 1 spray per nostril once weekly

Explanation: This question tests formulary substitution for intranasal corticosteroids in seasonal allergic rhinitis. The key patient-specific factor is the formulary covering only fluticasone propionate nasal spray, not mometasone. Fluticasone propionate nasal spray 2 sprays per nostril once daily is optimal as it provides equivalent potency and symptom relief. Option B is an asthma inhaler, inappropriate route, while option C uses oral antihistamine alone, less effective for nasal symptoms. Option D suggests incorrect weekly dosing, a common adherence error. Clinically, educate on proper nasal spray technique for efficacy. This substitution promotes cost-effectiveness via formulary-compliant generics.

Question 6

1. Switch to rivaroxaban 20 mg orally once daily with the evening meal (correct answer)
2. Switch to rivaroxaban 10 mg orally once daily
3. Switch to dabigatran 75 mg orally twice daily
4. Switch to aspirin 81 mg orally once daily

Explanation: This question tests formulary substitution among direct oral anticoagulants for atrial fibrillation. The key patient-specific factor is the formulary preferring rivaroxaban over apixaban, with CrCl 78 mL/min supporting standard dosing. Rivaroxaban 20 mg orally once daily with the evening meal is optimal for stroke prevention, matching efficacy with proper administration. Option B uses a reduced dose unnecessarily, while option C is dabigatran at a dose for lower CrCl. Option D suggests aspirin, inferior for AF anticoagulation. A pearl is to adjust DOAC doses based on renal function for safety. Formulary adherence ensures cost-effective anticoagulation without efficacy loss.

Question 7

1. Azithromycin 10 mg/kg orally on day 1, then 5 mg/kg orally daily on days 2 to 5 (correct answer)
2. Cephalexin 40 mg/kg/day orally divided twice daily for 10 days
3. Amoxicillin 90 mg/kg/day orally divided twice daily for 10 days
4. Azithromycin 5 mg/kg orally once daily for 2 days

Explanation: This question tests therapeutic class alternatives for acute otitis media in penicillin allergy. The key patient-specific factor is anaphylaxis to penicillin, precluding beta-lactams, during an amoxicillin/clavulanate shortage. Azithromycin 10 mg/kg on day 1, then 5 mg/kg daily on days 2 to 5 is optimal for its efficacy in AOM and safety in allergy. Option B uses cephalexin, risking cross-reactivity, while option C is amoxicillin, contraindicated. Option D suggests shortened azithromycin course, inadequate duration. Clinically, confirm allergy type before alternative selection. This approach ensures cost-effective treatment with appropriate duration.

Question 8

1. Switch to clopidogrel 75 mg orally once daily
2. Switch to prasugrel 10 mg orally once daily (correct answer)
3. Switch to warfarin with a target international normalized ratio (INR) of 2 to 3
4. Switch to prasugrel 5 mg orally once daily

Explanation: This question tests the concept of formulary substitution for P2Y12 inhibitors in acute coronary syndrome management. The key patient-specific factor is the history of urticarial rash with clopidogrel, indicating an allergy, combined with the hospital formulary not covering ticagrelor but covering prasugrel and clopidogrel. Switching to prasugrel 10 mg orally once daily is optimal because it provides equivalent antiplatelet efficacy for ACS without cross-reactivity to the clopidogrel allergy and aligns with formulary availability. Option A is incorrect as it involves clopidogrel, which is contraindicated due to allergy, while option C uses warfarin, which is not indicated for antiplatelet therapy in ACS and requires monitoring. Option D suggests a reduced prasugrel dose, which is suboptimal for this patient's weight and lacks indication for dose adjustment. A clinical pearl is to always check for allergies and formulary restrictions when substituting antiplatelet agents to ensure therapeutic equivalence. Emphasizing cost-effectiveness, prasugrel substitution maintains efficacy while complying with formulary guidelines.

Question 9

1. Switch to metoprolol succinate 50 mg orally once daily (correct answer)
2. Switch to metoprolol succinate 200 mg orally once daily
3. Switch to verapamil ER 240 mg orally once daily
4. Switch to metoprolol succinate 12.5 mg orally once daily

Explanation: This question assesses therapeutic interchange from a non-formulary beta-blocker to a preferred alternative for hypertension management, emphasizing dose equivalence. The key patient-specific factor is the current nebivolol 10 mg dose with uncontrolled blood pressure at 148/90 mmHg and no contraindications like asthma. Switching to metoprolol succinate 50 mg once daily is optimal as it provides an approximate equivalent antihypertensive effect within the formulary, supporting blood pressure control. Higher doses like 200 mg or lower like 12.5 mg are incorrect, as they may either overtreat or undertreat, leading to potential side effects or inefficacy. Verapamil is suboptimal as it is a calcium channel blocker, not a beta-blocker, and lacks class equivalence for this substitution. A clinical pearl is to use established dose conversion ratios, such as nebivolol 10 mg approximating metoprolol succinate 50 mg, when interchanging beta-blockers to maintain efficacy. Prioritizing formulary-preferred agents enhances cost-effectiveness and streamlines therapy in hypertension without unnecessary dose adjustments.

Question 10

1. Switch to loratadine 10 mg by mouth once daily (correct answer)
2. Switch to diphenhydramine 25 mg by mouth every 6 hours as needed
3. Switch to montelukast 10 mg by mouth once daily
4. Switch to loratadine 5 mg by mouth once daily

Explanation: This question tests appropriate antihistamine substitution considering both efficacy and patient-specific contraindications. The patient uses desloratadine, the active metabolite of loratadine, for allergic rhinitis and needs a formulary alternative. Loratadine 10 mg daily (A) is correct as it's the prodrug of desloratadine with equivalent efficacy at standard dosing - the body converts loratadine to desloratadine. Diphenhydramine (B) is contraindicated due to the patient's documented excessive sedation. Montelukast (C) is a leukotriene antagonist, not an antihistamine, representing a different drug class. Loratadine 5 mg (D) is half the standard adult dose and likely subtherapeutic. Understanding metabolite relationships helps guide appropriate substitutions - loratadine and desloratadine are essentially equivalent options, with loratadine being the more cost-effective choice.

Question 11

1. Dispense cefdinir 300 mg by mouth once daily for 7 days
2. Dispense azithromycin 500 mg by mouth once daily for 3 days
3. Dispense amoxicillin-clavulanate (amoxicillin component) 90 mg/kg/day divided twice daily for 7 days (correct answer)
4. Dispense amoxicillin-clavulanate (amoxicillin component) 25 mg/kg/day divided twice daily for 7 days

Explanation: This question addresses appropriate antibiotic substitution during drug shortages while maintaining guideline-recommended dosing for pediatric acute otitis media. The patient requires high-dose amoxicillin therapy (90 mg/kg/day) as first-line treatment for acute otitis media. Amoxicillin-clavulanate dosed at 90 mg/kg/day of the amoxicillin component (C) is correct, providing the same amoxicillin dose with added beta-lactamase inhibitor coverage. Cefdinir (A) is a second-line option that doesn't provide equivalent coverage to high-dose amoxicillin. Azithromycin (B) has high resistance rates and is reserved for true penicillin allergies. Amoxicillin-clavulanate at 25 mg/kg/day (D) represents standard dosing, not the high-dose regimen prescribed. During antibiotic shortages, maintain guideline-recommended dosing when substituting agents, and remember that amoxicillin-clavulanate dosing is based on the amoxicillin component.

Question 12

1. Switch to umeclidinium 62.5 mcg inhaled once daily (correct answer)
2. Switch to salmeterol 50 mcg inhaled twice daily
3. Switch to umeclidinium 62.5 mcg inhaled twice daily
4. Switch to ipratropium nebulizer 0.5 mg once daily

Explanation: This question tests formulary substitution among long-acting muscarinic antagonists for COPD. The key patient-specific factor is the formulary covering only umeclidinium, not tiotropium. Umeclidinium 62.5 mcg inhaled once daily is optimal for equivalent bronchodilation and convenience. Option B uses LABA, different class, while option C is twice-daily, incorrect frequency. Option D suggests short-acting ipratropium, suboptimal. A pearl is to screen for glaucoma before LAMAs. This substitution ensures cost-effective COPD control via formulary options.

Question 13

1. Switch to adapalene 0.1% gel applied once nightly (correct answer)
2. Switch to isotretinoin 40 mg orally twice daily
3. Switch to hydrocortisone 2.5% cream applied twice daily
4. Switch to adapalene 0.1% gel applied once weekly

Explanation: This question tests formulary substitution among topical retinoids for acne vulgaris. The key patient-specific factor is the formulary covering only adapalene 0.1% gel, not tretinoin. Adapalene 0.1% gel applied once nightly is optimal for its comparable comedolytic effects and better tolerability. Option B uses oral isotretinoin, for severe cases only, while option C is steroid, inappropriate. Option D suggests weekly application, inadequate frequency. A pearl is to advise sun protection with retinoids. Formulary generics ensure cost-effective acne treatment.

Question 14

1. Switch to generic levothyroxine 100 mcg orally once daily (correct answer)
2. Switch to liothyronine 25 mcg orally once daily
3. Switch to desiccated thyroid 60 mg orally once daily
4. Switch to generic levothyroxine 25 mcg orally once daily

Explanation: This question tests formulary substitution from brand to generic thyroid hormone replacement. The key patient-specific factor is the payer requiring generic levothyroxine over brand Synthroid. Generic levothyroxine 100 mcg orally once daily is optimal for maintaining euthyroid state with bioequivalence. Option B uses liothyronine, T3-only, while option C is desiccated thyroid, variable potency. Option D suggests low dose, inadequate. Clinically, monitor TSH post-switch for stability. Generic substitution emphasizes cost-effectiveness without therapeutic change.

Question 15

1. Switch to allopurinol 100 mg orally once daily (correct answer)
2. Switch to probenecid 500 mg orally once daily
3. Continue febuxostat 80 mg orally once daily
4. Switch to allopurinol 50 mg orally once weekly

Explanation: This question tests cost-effective alternatives for urate-lowering therapy in gout. The key patient-specific factor is the plan requiring allopurinol first over febuxostat, with normal renal function. Allopurinol 100 mg orally once daily is optimal as a starting dose for uric acid reduction at low cost. Option B uses probenecid, uricosuric alternative, while option C continues non-preferred febuxostat. Option D suggests weekly dosing, insufficient. A pearl is to titrate allopurinol gradually to avoid flares. Step therapy ensures cost-effective gout management.

Question 16

1. Switch to alfuzosin ER 10 mg orally once daily (correct answer)
2. Switch to finasteride 5 mg orally once daily only
3. Switch to doxazosin 8 mg orally once daily
4. Switch to alfuzosin ER 2.5 mg orally once daily

Explanation: This question tests formulary substitution among alpha-1 blockers for benign prostatic hyperplasia. The key patient-specific factor is the formulary preferring alfuzosin and the patient's dizziness history with doxazosin. Alfuzosin ER 10 mg orally once daily is optimal for its uroselectivity and lower orthostatic hypotension risk. Option B uses finasteride alone, different mechanism, while option C is doxazosin, previously intolerable. Option D suggests low dose, insufficient. A pearl is to select uroselective agents in hypotensive risk. This ensures cost-effective, tolerable therapy via formulary options.

Question 17

1. Switch to dapagliflozin 10 mg orally once daily (correct answer)
2. Switch to glyburide 10 mg orally once daily
3. Switch to canagliflozin 100 mg orally once daily (non-formulary)
4. Switch to dapagliflozin 2.5 mg orally once daily

Explanation: This question tests formulary substitution among SGLT2 inhibitors for type 2 diabetes with cardiovascular benefits in CKD. The key patient-specific factor is the insurance requiring step therapy and covering dapagliflozin but not empagliflozin, alongside an eGFR of 52 mL/min/1.73 m² suitable for initiation. Dapagliflozin 10 mg orally once daily is optimal as it provides similar cardiorenal protection and is formulary-approved without dose adjustment needed. Option B uses glyburide, which risks hypoglycemia in CKD, while option C is non-formulary canagliflozin, violating coverage. Option D suggests a suboptimal low dose of dapagliflozin, common error in overlooking standard dosing. Clinically, always verify eGFR compatibility when substituting SGLT2 inhibitors for safety. This approach emphasizes cost-effectiveness through formulary adherence while maintaining therapeutic efficacy.

Question 18

1. Switch to itraconazole 200 mg by mouth once daily for 12 weeks (correct answer)
2. Switch to terbinafine 125 mg by mouth once daily for 12 weeks
3. Switch to acyclovir 400 mg by mouth three times daily for 10 days
4. Switch to itraconazole 100 mg by mouth once weekly for 12 weeks

Explanation: This question evaluates selection of alternative antifungal therapy for onychomycosis in a patient with documented terbinafine allergy. The patient experienced angioedema and urticaria with terbinafine, representing a severe hypersensitivity reaction requiring complete avoidance of this agent. Itraconazole 200 mg daily for 12 weeks (A) is correct as it provides effective systemic azole therapy for toenail onychomycosis using continuous dosing. Terbinafine at any dose (B) is absolutely contraindicated given the severe allergic reaction. Acyclovir (C) is an antiviral with no activity against fungal infections. Itraconazole 100 mg weekly (D) represents pulse dosing for fingernail infections, not the continuous therapy needed for toenails. When managing antifungal allergies, switch to a different drug class entirely, and remember that itraconazole requires adequate dosing (200 mg daily or pulse therapy) for nail penetration.

Question 19

1. Switch to warfarin 5 mg by mouth once daily with international normalized ratio monitoring
2. Switch to rivaroxaban 20 mg by mouth once daily with the evening meal (correct answer)
3. Switch to dabigatran 150 mg by mouth twice daily
4. Switch to rivaroxaban 10 mg by mouth once daily

Explanation: This question addresses formulary substitution of direct oral anticoagulants (DOACs) while considering patient-specific monitoring barriers. The patient has transportation difficulties making warfarin monitoring challenging, so a DOAC alternative is preferred. Rivaroxaban 20 mg once daily with food (B) is correct, providing equivalent stroke prevention in atrial fibrillation with once-daily dosing. Warfarin (A) requires frequent INR monitoring, which the patient cannot reliably obtain. Dabigatran (C) is not listed as a formulary option. Rivaroxaban 10 mg (D) is the dose for venous thromboembolism treatment, not atrial fibrillation. When substituting DOACs, verify indication-specific dosing and remember that rivaroxaban for atrial fibrillation must be taken with the evening meal to ensure adequate absorption of the 20 mg dose.

Question 20

1. Continue simvastatin 40 mg by mouth nightly and add coenzyme Q10 200 mg daily
2. Switch to rosuvastatin 5 mg by mouth once daily (correct answer)
3. Switch to gemfibrozil 600 mg by mouth twice daily
4. Switch to atorvastatin 80 mg by mouth once daily

Explanation: This question evaluates management of statin-induced myopathy and appropriate therapeutic alternatives within formulary constraints. The patient presents with classic signs of statin myopathy including muscle aches, weakness, dark urine, and significantly elevated creatine kinase (980 U/L), requiring immediate discontinuation of simvastatin. Rosuvastatin 5 mg daily (B) is correct as it represents a lower-intensity statin option from the preferred formulary list, which may be better tolerated given her previous tolerance of pravastatin. Continuing simvastatin with coenzyme Q10 (A) is inappropriate as the statin must be discontinued with CK elevation >10 times upper limit of normal. Gemfibrozil (C) is not a statin alternative and carries its own myopathy risk. Atorvastatin 80 mg (D) represents high-intensity statin therapy, which would likely cause recurrent myopathy. When managing statin intolerance, consider switching to a lower intensity statin or hydrophilic options like rosuvastatin or pravastatin, which may have lower myopathy risk.